A randomized phase II trial of fludarabine, cyclophosphamide and mitoxantrone (FCM) with or without rituximab in previously treated chronic lymphocytic leukaemia

British Journal of Haematology

Volumn 152, Issue 5, 2011, Pages 570-578

  Hillmen, Peter ^a   Cohen, Dena R ^b   Cocks, Kim ^b   Pettitt, Andrew ^c   Sayala, Hazem A ^a   Rawstron, Andy C ^a,d   Kennedy, Daniel B ^e   Fegan, Christopher ^f   Milligan, Don W ^g   Radford, John ^h   Mercieca, Jane ⁱ   Dearden, Claire ^j   Ezekwisili, Raphael ^k   Smith, Alexandra F ^b   Brown, Julia ^b   Booth, Gillian A ^b   Varghese, Abraham M ^a   Pocock, Christopher ^l  

^a LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c ROYAL LIVERPOOL UNIVERSITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF YORK   (United Kingdom)

^e LEICESTER ROYAL INFIRMARY   (United Kingdom)

^f UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^g BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^h CHRISTIE HOSPITAL   (United Kingdom)

ⁱ ST HELIER HOSPITAL   (United Kingdom)

^j ROYAL MARSDEN HOSPITAL   (United Kingdom)

^k DARENT VALLEY HOSPITAL   (United Kingdom)

^l EAST KENT HOSPITALS UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Chronic lymphocytic leukaemia; Cyclophosphamide; Fludarabine; Minimal residual disease; Mitoxantrone; Phase II study; Rituximab

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; RITUXIMAB;

ADULT; AGED; ARTICLE; BLOOD DISEASE; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GENE MUTATION; HUMAN; IMMUNE DEFICIENCY; INFECTION; INFLAMMATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; MINIMAL RESIDUAL DISEASE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; RESPIRATORY TRACT DISEASE; SKIN DISEASE; SOFT TISSUE DISEASE; SUBCUTANEOUS TISSUE DISEASE; THORAX DISEASE; TREATMENT RESPONSE; UROGENITAL TRACT DISEASE;

ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOPHOSPHAMIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; MITOXANTRONE; NEOPLASM, RESIDUAL; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VIDARABINE;

EID: 79951521940     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08317.x     Document Type: Article

References (26)

1. Bosch, F., Ferrer, A., Lopez-Guillermo, A., Gine, E., Bellosillo, B., Villamor, N., Colomer, D., Cobo, F., Perales, M., Esteve, J., Altes, A., Besalduch, J., Ribera, J.M. & Montserrat, E. & For the GELCAB (Grup per l'Estudi dels Limfomes) (2002) Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia. British Journal of Haematology, 119, 976-984.
2. Bosch, F., Ferrer, A., Villamor, N., Gonzalez, M., Briones, J., Gonzalez-Barca, E., Abella, E., Gardella, S., Escoda, L., Perez-Ceballos, E., Peschel, C., Asensi, A., Sayas, M.J., Font, L., Altes, A., Muntanola, A., Bertazzoni, P., Rozman, M., Aymerich, M., Gine, E. & Montserrat, E. (2008) Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clinical Cancer Research, 14, 155-161.
3. Bosch, F., Abrisqueta, P., Villamor, N., Terol, M.J., Gonzalez-Barca, E., Ferra, C., Gonzalez Diaz, M., Abella, E., Delgado, J., Carbonell, F., Garcia Marco, J.A., Escoda, L., Ferrer, S., Monzo, E., Gonzalez, Y., Estany, C., Jarque, I., Salamero, O., Muntanola, A. & Montserrat, E. (2009) Rituximab, fludarabine, cyclophosphamide, and mitoxantrone: a new, highly active chemoimmunotherapy regimen for chronic lymphocytic leukemia. Journal of Clinical Oncology, 27, 4578-4584.
4. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M.J.S., Bezares, R.F., Pettitt, A.R., Hamblin, T., Milligan, D.W., Child, J.A., Hamilton, M.S., Dearden, C.E., Smith, A.G., Bosanquet, A.G., Davis, Z., Brito-Babapulle, V., Else, M., Wade, R. & Hillmen, P. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. The Lancet, 370, 230-239.
5. Cheson, B.D., Bennett, J.M., Grever, M., Kay, N., Keating, M.J., O'Brien, S. & Rai, K.R. (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood, 87, 4990-4997.
6. Foran, J.M., Rohatiner, A.Z.S., Cunningham, D., Popescu, R.A., Solal-Celigny, P., Ghielmini, M., Coiffier, B., Johnson, P.W.M., Gisselbrecht, C., Reyes, F., Radford, J.A., Bessell, E.M., Souleau, B., Benzohra, A. & Lister, T.A. (2000) European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for Patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small b-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317-324.
7. Goldman, A.I. & Hannan, P.J. (2001) Optimal continuous sequential boundaries for monitoring toxicity in clinical trials: a restricted search algorithm. Statistics in Medicine, 20, 1575-1589.
8. Hainsworth, J.D., Litchy, S., Barton, J.H., Houston, G.A., Hermann, R.C., Bradof, J.E. & Greco, F.A. (2003) Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase ii trial of the Minnie Pearl Cancer Research Network. Journal of Clinical Oncology, 21, 1746-1751.
9. Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A.M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Grünhagen, U., Bergmann, M., Catalano, J., Zinzani, P.L., Caligaris-Cappio, C., Seymour, J.F., Berrebi, A., Jäger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C.M., Eichhorst, B.F., Staib, P., Bühler, A., Winkler, D., Zenz, T., Böttcher, S., Ritgen, M., Mendila, M., Kneba, M., Döhner, H., Stilgenbauer, S.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label phase 3 trial. Lancet, 376, 1164-74.
10. Hallek, M., Cheson, B.D., Catovsky, D., Cligaris-Cappio, F., Dighiero, G., Dohner, H., Hillmen, P., Keating, M.J., Montserrat, E., Rai, K.R. & Kipps, T.J. (2008) Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood, 111, 5446-5456.
11. Hendry, L., Bowen, A., Matutes, E., Swansbury, J. & Catovsky, D. (2004) Fludarabine, cyclophosphamide and mitoxantrone in relapsed or refractory chronic lymphocytic leukemia and low grade non-hodgkin's lymphoma. Leukemia and Lymphoma, 45, 945-950.
12. Huhn, D., von Schilling, C., Wilhelm, M., Ho, A.D., Hallek, M., Kuse, R., Knauf, W., Riedel, U., Hinke, A., Srock, S., Serke, S., Peschel, C. & Emmerich, B. (2001) Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood, 98, 1326-1331.
13. Itälä, M., Geisler, C.H., Kimby, E., Juvonen, E., Tjonnfjord, G., Karlsson, K. & Remes, K. (2002) Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. European Journal of Haematology, 69, 129-134.
14. Kwok, M., Rawstron, A.C., Varghese, A. & Hillmen, P. (2009) Minimal residual disease is a predictor for progression-free and overall survival in chronic lymphocytic leukemia (cll) that is independent of the type or line of therapy. (Abstract). ASH Annual Meeting Abstracts, 114, 540.
15. Machin, D., Campbell, M.J., Fayers, P.M. & Pinol, A.P.Y. (1997) Sample Size Tables for Clinical Studies, 2nd edn. Blackwell Science Ltd, Oxford.
16. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., ce-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825-2833.
17. Moher, D., Schulz, K.F. & Altman, D.G. for the CONSORT Group (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Annals of Internal Medicine, 134, 657-662.
18. Nguyen, D.T., Amess, J.A., Doughty, H., Hendry, L. & Diamond, L.W. (1999) IDEC-C2B8 anti-CD20 (Rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. European Journal of Haematology, 62, 76-82.
19. Rawstron, A.C., Kennedy, B., Evans, P.A., Davies, F.E., Richards, S.J., Haynes, A.P., Russell, N.H., Hale, G., Morgan, G.J., Jack, A.S. & Hillmen, P. (2001) Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood, 98, 29-35.
20. Rawstron, A.C., Villamor, N., Ritgen, M., Bottcher, S., Ghia, P., Zehnder, J.L., Lozanski, G., Colomer, D., Moreno, C., Geuna, M., Evans, P.A.S., Natkunam, Y., Coutre, S.E., Avery, E.D., Rassenti, L.Z., Kipps, T.J., Caligaris-Cappio, F., Kneba, M., Byrd, J.C., Hallek, M.J., Montserrat, E. & Hillmen, P. (2007) International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia, 21, 956-964.
21. Robak, T., Moiseev, S.I., Dmoszynska, A., Solal-Celigny, P., Warzocha, K., Loscertales, J., Catalano, J., Afanasiev, B.V., Larratt, L., Geisler, C., Montillo, M., Ganly, P., Dartigeas, C., Rosta, A., Janssens, A., Mendila, M., Maurer, J. & Wenger, M.K. (2008) Rituximab, fludarabine, and cyclophosphamide (r-fc) prolongs progression free survival in relapsed or refractory chronic lymphocytic leukemia (cll) compared with fc alone: final results from the international randomized phase iii reach trial. (Abstract). Blood (ASH Annual Meeting Abstracts), 112, lba-1.
22. Van Glabbeke, M., Steward, W. & Armand, J.P. (2002) Non-randomised phase II trials of drug combinations: often meaningless, sometimes misleading. Are there alternative strategies? European Journal of Cancer, 38, 635-638.
23. Wierda, W., O'Brien, S., Wen, S., Faderl, S., Garcia-Manero, G., Thomas, D., Do, K.A., Cortes, J., Koller, C., Beran, M., Ferrajoli, A., Giles, F., Lerner, S., Albitar, M., Kantarjian, H. & Keating, M. (2005) Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. Journal of Clinical Oncology, 23, 4070-4078.
24. Wilder, D.D., Ogden, J.L. & Jain, V.K. (2002) Efficacy of fludarabine/mitoxantrone/dexamethasone alternating with CHOP in bulky follicular non-Hodgkin's lymphoma. Clinical Lymphoma, 2, 229-237.
25. Winkler, U., Jensen, M., Manzke, O., Schulz, H., Diehl, V. & Engert, A. (1999) Cytokine-release syndrome in patients with b-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood, 94, 2217-2224.
26. Zinzani, P.L., Magagnoli, M., Moretti, L., Battista, R., Ronconi, F., De Renzo, A., Zaccaria, A., Gentilini, P., Guardigni, L., Gherlinzoni, F., Cellini, C., Fattori, P.P., Bendandi, M., Bocchia, M., Aitini, E. & Tura, S. (1999) Fludarabine-based chemotherapy in untreated mantle cell lymphomas: an encouraging experience in 29 patients. Haematologica, 84, 1002-1006.